David A Quigley
Overview
Explore the profile of David A Quigley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharifi M, Feng E, Rydzewski N, Taylor A, Sperger J, Shi Y, et al.
Mol Oncol
. 2025 Feb;
PMID: 39985777
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we...
2.
Chesner L, Polesso F, Graff J, Hawley J, Smith A, Lundberg A, et al.
Cancer Discov
. 2024 Dec;
15(3):481-494.
PMID: 39652470
Immunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This...
3.
Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, et al.
J Clin Invest
. 2024 Oct;
134(19).
PMID: 39352383
BACKGROUNDAndrogen receptor signaling inhibitors (ARSIs) have improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), but their clinical benefit is limited by treatment resistance.METHODSTo investigate the mechanisms of ARSI...
4.
Chou J, Robinson T, Egusa E, Lodha R, Zhang M, Badura M, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5445-5458.
PMID: 39321214
Purpose: The cyclin-dependent kinase (CDK), CDK12, is mutated or amplified in multiple cancers. We previously described a subtype of prostate cancer characterized predominantly by frameshift, loss-of-function mutations in CDK12. This...
5.
Zhao S, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, et al.
Nat Genet
. 2024 Jul;
56(8):1689-1700.
PMID: 39020220
The impact of variations in the three-dimensional structure of the genome has been recognized, but solid cancer tissue studies are limited. Here, we performed integrated deep Hi-C sequencing with matched...
6.
Shrestha R, Chesner L, Zhang M, Zhou S, Foye A, Lundberg A, et al.
Cancer Res
. 2024 Jul;
84(18):3086-3100.
PMID: 38990734
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that resists therapy targeting androgen signaling, the primary driver of prostate cancer. mCRPC resists androgen receptor (AR) inhibitors by amplifying AR...
7.
Zhu X, Chan E, Turski M, Mendez C, Hsu S, Kumar V, et al.
Oncologist
. 2024 Jun;
29(8):e1094-e1097.
PMID: 38908022
HER2, encoded by the ERBB2 gene, is an important druggable driver of human cancer gaining increasing importance as a therapeutic target in urothelial carcinoma (UC). The genomic underpinnings of HER2...
8.
Subramanian A, Zhang M, Sharifi M, Moreno-Rodriguez T, Feng E, Rydzewski N, et al.
bioRxiv
. 2024 Jun;
PMID: 38895460
Background: Prostate cancer is a heterogenous disease, but once it becomes metastatic it eventually becomes treatment resistant. One mechanism of resistance to AR-targeting therapy is lineage plasticity, where the tumor...
9.
Zhang M, Sjostrom M, Cui X, Foye A, Farh K, Shrestha R, et al.
Nat Cell Biol
. 2024 Jun;
26(7):1176-1186.
PMID: 38871824
Transcription factor (TF) proteins regulate gene activity by binding to regulatory regions, most importantly at gene promoters. Many genes have alternative promoters (APs) bound by distinct TFs. The role of...
10.
Saha D, Dang H, Zhang M, Quigley D, Feng F, Maher C
NPJ Genom Med
. 2024 Feb;
9(1):14.
PMID: 38396008
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal form of prostate cancer. Although long-noncoding RNAs (lncRNAs) have been implicated in mCRPC, past studies have relied on bulk sequencing methods with...